辅助性表皮生长因子受体抑制剂的疗效及临床因素对切除的表皮生长因子受体突变型非小细胞肺癌的影响：一项荟萃分析

Efficacy of adjuvant EGFR inhibitors and impact of clinical factors in resected -mutated non-small-cell lung cancer: a meta-analysis.

作者信息

Li Meichen, Hou Xue, Lin Suxia, Zheng Lie, Liang Jianzhong, Chen Jing, Wang Na, Zhang Baishen, Chen Likun

机构信息

Department of Medical Oncology, Sun Yat-Sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, PR China.

Department of Pathology, Sun Yat-Sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, PR China.

出版信息

Future Oncol. 2022 Mar;18(9):1159-1169. doi: 10.2217/fon-2021-0934. Epub 2022 Feb 3.

DOI:10.2217/fon-2021-0934

PMID:35109665

Abstract

The role of adjuvant EGFR tyrosine kinase inhibitors (TKIs) in resected -mutated non-small-cell lung cancer (NSCLC) remains unclear. We evaluated pooled hazard ratio and 95% CI for disease-free survival, overall survival and prespecified subgroups. Seven prospective studies with 1288 patients were included in the meta-analysis. Adjuvant EGFR TKIs significantly improved disease-free survival in -mutated resected NSCLC (HR: 0.41; 95% CI: 0.24-0.70) and in all subgroups. However, the overall survival benefit was not significant (HR: 0.65; 95% CI: 0.36-1.17). The benefit of adjuvant TKIs may be associated with TKI regimens, treatment duration, pathological stage and mutation type. Adjuvant EGFR TKIs significantly improved disease-free survival and nonsignificantly improved overall survival in resected -mutated NSCLC.

摘要

辅助性表皮生长因子受体酪氨酸激酶抑制剂（TKIs）在已切除的表皮生长因子受体（EGFR）突变的非小细胞肺癌（NSCLC）中的作用仍不明确。我们评估了无病生存期、总生存期及预先设定亚组的合并风险比和95%置信区间。该荟萃分析纳入了7项涉及1288例患者的前瞻性研究。辅助性EGFR TKIs显著改善了EGFR突变的已切除NSCLC患者的无病生存期（风险比：0.41；95%置信区间：0.24 - 0.70），且在所有亚组中均如此。然而，总生存期获益并不显著（风险比：0.65；95%置信区间：0.36 - 1.17）。辅助性TKIs的获益可能与TKI治疗方案、治疗持续时间、病理分期及EGFR突变类型有关。辅助性EGFR TKIs显著改善了EGFR突变的已切除NSCLC患者的无病生存期，对总生存期的改善不显著。